WillItSurvive
No grouping · Canada

Satellos Bioscience Inc.

Pre-revenue biotech testing SAT-3247, an oral DMD drug, in small human trials.

Losing its protection
Assessed 29 July 2026 · Evidence as of 29 July 2026
The structural protection is eroding.
On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: BASECAMP pediatric Phase 2 DMD trial readout on functional endpoints
The call

Satellos is a single-drug company whose fate rests on a small pediatric trial's outcome expected in late 2026.

Satellos is a very young drug company with no approved products, only one experimental treatment called SAT-3247 for a muscle disease called DMD. Right now, the company's future depends entirely on whether this single drug works in patients, which hasn't been proven yet; if it fails, the company likely disappears. Sarepta Therapeutics dominates DMD treatment today but has stumbled recently and faces new competitors, which could open a door for Satellos if its drug shows real benefits in upcoming patient trials, though the odds are uncertain and the company will need more money to keep going.

Why
01
AI pressure: None apparent. No AI product competes here; AI-driven drug discovery could speed rival DMD programs later, but none does yet. Could AI do the core job? Unlikely.
02
Bigger players: Sarepta Therapeutics. Sarepta already sells approved DMD therapies and gene therapy while Satellos has nothing on the market yet. Could a giant copy it? Probably.
03
What protects it. FDA Fast Track status and a licensed AAK1 mechanism that may work regardless of a patient's dystrophin mutation.
What would change this call
BASECAMP pediatric Phase 2 readout on functional/motor endpoints, expected H2 2026. Shows whether SAT-3247 works beyond the small n=4 MRI surrogate signal.
Dyne Therapeutics DYNE-251 FDA decision on Jan 21, 2027. Would show a rival DMD therapy reaching market ahead of Satellos.
Terms of Satellos' next capital raise before its 2027 cash runway ends. Would show whether investors still believe in the trial data enough to fund without heavy dilution.
Key numbers
  • $57.2M raised in public offering at $10.10/share (2026-02-09)
  • n=4 patients showed 3.7pt drop in muscle fat fraction (2026-07-08)
  • Cash runway extends through 2027 after raise (2026-03-27)
Named risks
  • Single-asset dependency on SAT-3247 with no approved product or revenue as of mid-2026. Severity: high
  • BASECAMP pediatric trial failure or lack of functional/motor benefit beyond MRI surrogate. Severity: high
  • Interim TRAILHEAD efficacy signal based on only 4 patients, flagged by independent commentary as inviting skepticism. Severity: medium
  • Crowded competitive field with better-funded rivals (Novartis, Dyne, REGENXBIO) advancing faster toward approval. Severity: high
  • Cash runway guided only through 2027, dependent on no enrollment delays or additional dilutive raises. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Sarepta Therapeuticsgaining onSarepta's confirmatory ESSENCE trial failed in late 2025, opening a gap Satellos and rivals target
Dyne Therapeuticslosing toDYNE-251 has FDA priority review with decision expected January 21, 2027, ahead of Satellos's approval timeline
Novartis/Avidity Bioscienceslosing toNovartis acquired Avidity for $12B in 2025; its AOC 1044 therapy is already in Phase 3 (SAFARI44)
Solid BiosciencescontestingSGT-003 gene therapy Phase 3 IMPACT DUCHENNE enrolled first patient Q1 2026
REGENXBIOlosing toRGX-202 gene therapy planning mid-2026 regulatory filing, ahead of Satellos's Phase 2 stage
Questions people ask
Is Satellos Bioscience profitable in 2026?
No. Satellos is a pre-revenue clinical-stage biotech with no approved product; trailing-twelve-month revenue is reported as N/A as of March 10, 2026. Its lead asset SAT-3247 is still in Phase 2 trials for Duchenne muscular dystrophy, so profitability is not expected until after regulatory approval, if ever.
Could AI replace Satellos Bioscience's work?
Unlikely to replace it outright. Satellos' core work is wet-lab drug discovery and regulated clinical trials for SAT-3247; AI can accelerate biomarker modeling but cannot substitute for FDA review or biological proof of efficacy, which is why its June 29, 2026 Fast Track designation still required human clinical data.
Who is Satellos Bioscience's biggest competitor?
Sarepta Therapeutics is the dominant incumbent in Duchenne muscular dystrophy, though it suffered a failed confirmatory ESSENCE trial in late 2025. Other rivals advancing faster toward approval include Dyne Therapeutics (FDA decision expected January 21, 2027) and Novartis-owned Avidity Biosciences (acquired for $12B in 2025).
Is Satellos Bioscience running out of money?
Not immediately. After closing a US$57.2 million public offering on February 9, 2026 at US$10.10 per share, Satellos reported in its March 27, 2026 full-year results that cash runway now extends through 2027, giving it roughly a year and a half of buffer as of mid-2026.
Who owns Satellos Bioscience?
Satellos Bioscience is a publicly traded company with no parent, dual-listed on the TSX under MSCL and cross-listed on Nasdaq under MSLE since around February 2026, when it completed a US$57.2 million public offering alongside its US listing.
What is Satellos Bioscience's stock worth in 2026?
As of July 29, 2026, Satellos traded at US$9.42 per share on Nasdaq (MSLE), with a TSX market cap (MSCL) of approximately C$278 million. Shares have been highly volatile, falling 18.11% on March 10, 2026 after MDA trial data and swinging double digits around clinical news.
Timeline
  • 2026-07-08Six-month interim TRAILHEAD data in 4 DMD patients shows 3.7pp fat-fraction reduction, stable strength
  • 2026-06-29SAT-3247 receives FDA Fast Track designation for Duchenne muscular dystrophy
  • 2026-03-27Full-year 2025 results report cash runway extended through 2027
  • 2026-03-10Stock falls 18.11% following MDA muscular dystrophy data presentation
  • 2026-02-09US$57.2 million public offering closes at US$10.10 per share, upsized via over-allotment
  • 2026-02-06Satellos prices US$50 million public offering ahead of Nasdaq cross-listing
  • 2025-11-13Q3 2025 results show cash balance of $48.2M CAD/$34.6M USD pre-offering
  • 2025-03-25Phase 1a/1b CL-101 data reported
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
American Airlines GroupSafe Superintelligence Inc.Wayfair
More companies losing its protection →
Sources